The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The evolving role of iberdomide for treating multiple myeloma beyond dara-based triplets
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the evolving role of the CELMoD, iberdomide, beyond daratumumab-based triplets, considering its potential as a combination partner for bispecific and trispecific therapies. Prof. Lonial highlights its potential to induce deep, rapid responses when paired with agents like elranatamab in patients with multiple myeloma. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In my mind, combinations of the CELMoDs and particularly iberdomide with bispecifics or as an adjunct to CAR-Ts really is the future. In my mind, I always wonder, what is the better partner for a bispecific? Is it an anti-CD38 antibody, as we saw in MajesTEC-3, or is it a CELMoD? As we’ve seen exciting data from MagnetisMM-30, for instance, that combines iber with elra...
In my mind, combinations of the CELMoDs and particularly iberdomide with bispecifics or as an adjunct to CAR-Ts really is the future. In my mind, I always wonder, what is the better partner for a bispecific? Is it an anti-CD38 antibody, as we saw in MajesTEC-3, or is it a CELMoD? As we’ve seen exciting data from MagnetisMM-30, for instance, that combines iber with elra. Really, really deep responses, very quick responses. And ultimately, we’re trying to get to time-limited therapy, and this combination may be a way to get there.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
